Boosting anticancer immunotherapy through androgen receptor blockade

Cancer Cell. 2022 May 9;40(5):455-457. doi: 10.1016/j.ccell.2022.04.007. Epub 2022 May 9.

Abstract

Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8+ T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.

Trial registration: ClinicalTrials.gov NCT03753243.

MeSH terms

  • Cell Line, Tumor
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Male
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Receptors, Androgen*

Substances

  • Immune Checkpoint Inhibitors
  • Receptors, Androgen

Associated data

  • ClinicalTrials.gov/NCT03753243